All given 30 minutes before chemotherapy, except rolapitant which is given 1 to 2 hours before chemotherapy.
The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (>24 hours) use of these agents, making a steroid or steroid and dopamine antagonist combination most appropriate for follow-up therapy. 17 One of the following regimens is recommended: Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [13] [14] [15] [16] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is not recommended. [17] [18] [19] [20] [21] [22] B. Breakthrough Nausea and Vomiting [13] [14] [15] [16] : Patients should receive a prescription for an antiemetic to 6 2. Capecitabine 1700 mg/m 2 /day days 1-14; oxaliplatin 130 mg/m 2 day 1, bevacizumab 7.5 mg/kg day 1, every 14 days. 7 3. Capecitabine 2000 mg/m 2 /day days 1-14; oxaliplatin 85 mg/m 2 day 1, bevacizumab 10 mg/kg day 1, every 14 days. 8 4. Capecitabine 1500 mg/m 2 /day days 1-14; oxaliplatin 130 mg/m 2 day 1, bevacizumab 7.5 mg/kg day 1, every 21 days. 9
Note. IV = intravenous; PO = oral. treat breakthrough nausea. One of the following regimens is recommended: 
C. Hypersensitivity Precautions:
Oxaliplatin is reported to cause hypersensitivity reactions in 8% to 13% of patients, with the incidence of moderate to severe reactions ranging from <1% to 7%. The most common symptoms are flushing and swelling of the face and hands, itching, sweating, lacrimation, skin rash, hives, rigors, dyspnea, and fever. Such reactions usually occur during the second or subsequent cycles, but one study suggests that the reactions most often occur around cycle 9 or 10. [23] [24] [25] For mild reactions, the oxaliplatin infusion is stopped and an antihistamine and a corticosteroid may be administered. Moderate to severe reactions usually require administration of parenteral corticosteroids. One report suggests that lengthening the oxaliplatin infusion time from 2 to 6 hours reduces the incidence of hypersensitivity reactions and may be appropriate for some patients. Premedication with corticosteroids and antihistamines does not prevent subsequent hypersensitivity reactions. 23 If the reaction to oxaliplatin is determined to be anaphylactic, a desensitization regimen may be necessary for future doses. 25
D. Hematopoietic Growth Factors: Accepted practice
guidelines and pharmacoeconomic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony-stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 26, 27 Because febrile neutropenia was reported in 1% to 2% of patients and grade 3 or 4 neutropenia was reported in 4% to 22% of patients in the trials reviewed, 1-4 primary prophylactic use of CSFs is not recommended. [1] [2] [3] [4] CSFs should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of BCapOx.
E. Diarrhea:
Diarrhea is a frequent consequence of capecitabine administration.
Diarrhea is usually mild to moderate, responding to conventional therapy. Occasionally, the problem can be severe or dose-limiting.
Patients should receive a prescription for an antidiarrheal agent for use at the onset of diarrhea. The standard recommendation is loperamide 4 mg PO at the onset of diarrhea, followed by 2 mg PO every after each unformed stool, or as often as every 2 hours for 24 hours. 28 Patients should be counseled to 29 
F. Neurotoxicity:
Neurotoxicity was reported in 1% to 83% of patients receiving BCapOx, 1-5 with grade 3 or 4 neurotoxicity reported in 8% to 26% of patients. [1] [2] [3] [4] [5] Oxaliplatin causes acute neurotoxicity consisting of coldinduced or cold-exacerbated paresthesias/dysesthesias and muscle contractions. It also causes chronic neurotoxicity that can impair quality of life. Preclinical data suggest the acute neurotoxicity may be due to oxaliplatin's effects on voltagedependent sodium channels and/or chelation of intracellular calcium by the oxaliplatin metabolite, oxalate. 30 IV infusion of 1 g each of calcium gluconate and magnesium sulfate before and after the oxaliplatin infusion was reported to significantly reduce the incidence of neurotoxicity. [31] [32] [33] Recent data indicate that this is not effective. The use of calcium gluconate and magnesium sulfate is no longer recommended. 34 
Major Toxicities
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. [1] [2] [3] 5 (grade 3 or 4) 4% to 16%. 1-3,5 C. Dermatologic: Alopecia (grade 1 or 2) 2%, 1 skin hyperpigmentation (grade 1 or 2) 2% to 43%. 1 D. Gastrointestinal: Anorexia (all grades) 3% to 34%, [1] [2] [3] (grade 3 or 4) 3% to 13% 1 ; diarrhea (all grades) 1% to 62%, [1] [2] [3] [4] [5] to begin a cycle with full-dose therapy in the protocols reviewed were: 1. Absolute neutrophil count (ANC), greater than or equal to 1500 cells/mcL. 1-3,5,10 2. White blood cell (WBC) count, greater than or equal to 3,000 cell/mcL. 2 3. Hemoglobin, greater than or equal to 9 g/dL. [1] [2] [3] 5 4. Platelet count, greater than or equal to 100 000 cells/mcL. 2,3,5,10 5. Renal function a. Serum creatinine, within normal institutional limits 2, 4 or less than or equal to 1.5 times the upper normal limit (ULN) 1, 3 or less than or 2 mg/dL. 5 b. Creatinine clearance, greater than or equal to 50 mL/min or greater than or equal to 30 mL/min. 2,3,5 c. Proteinuria, less than grade 1 1 or less than 2+ for protein 11 or urine protein creatinine ratio less than or equal to 1. 5 6. Hepatic function a. Total bilirubin, less than or equal to 2 mg/dL 1 or less than or equal to 1.5 times the UNL. 2,3,5,10 b. ALT/AST, less than or equal to 2.5 times the upper limit of normal 1-3,5,10 or less than or equal to 5 times the UNL if liver metastases were present. 1,3,5 c. Alkaline phosphatase, less than or equal to 2.5 times the UNL 5,10 or less than or equal to 5 times the UNL if liver metastases were present or less than or equal to 10 times the UNL if bone metastases were present. 5 In clinical practice, a pretreatment ANC of 1000 cells/ mcL and platelets of 75 000 cells/mcL are usually considered acceptable.
A. Cardiovascular

Dosage Modifications
A. Renal Function
1. Capecitabine: Creatinine clearance a. 30 to 50 mL/min, reduce dose by 25%. 3, 5, 35, 36 b. Less than 30 mL/min, do not give drug. 35 
Oxaliplatin: Creatinine clearance
a. Greater than 20 mL/min, give 100% dose. 37 b. Greater than or equal to 30 mL/min, give 100% dose. 38 
